Soluble tumor necrosis factor receptor type I enhances tumor development and persistence in vivo.

No abstract is available for this paper.

• Publication year

  2000

• Venue

  Cellular Immunology

• Publication date

  2000-03-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1006/CIMM.2000.1622PMID 10753499
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The role of therapeutic apheresis in the treatment of cancer: a review.

  1999cited by this paper
• Multifaceted inhibition of anti‐tumour imm_une mechanisms by soluble tumour necrosis factor receptor type I

  1998cited by this paper
• Delayed rejection of soluble tumor necrosis factor receptor-secreting tumor allografts.

  1998cited by this paper
• Cerebrospinal fluid concentrations of soluble tumor necrosis factor receptor in bacterial and aseptic meningitis

  1996cited by this paper
• Serum levels of soluble receptors for tumor necrosis factor (p55 and p75 sTNFr) in endometrial cancer.

  1996cited by this paper
• LOW MOLECULAR WEIGHT PROTEIN APHERESIS AND REGRESSION OF BREAST CANCER

  1996cited by this paper
• Increased release of the tumour necrosis factor receptor p75 by immortalized human keratinocytes results from an activated shedding mechanism and is not related to augmented steady-state levels of p75 mRNA

  1996cited by this paper
• Anti‐Tumor Activity of Cytotoxic T Lymphocytes Elicited with Recombinant and Synthetic Forms of a Model Tumor‐Associated Antigen

  1995cited by this paper
• Serum soluble markers of immune activation and disease activity in systemic lupus erythematosus

  1995cited by this paper
• Active immunotherapy of cancer with a nonreplicating recombinant fowlpox virus encoding a model tumor-associated antigen.

  1995cited by this paper
• Increased levels of soluble tumor necrosis factor receptor in patients with multiple sclerosis and HTLV-1-associated myelopathy.

  1994cited by this paper
• Selective release of tumor necrosis factor binding protein II by malignant human epidermal cells reveals protection from tumor necrosis factor alpha-mediated cytotoxicity.

  1994cited by this paper
• Increased plasma concentrations for type I and II tumor necrosis factor receptors and IL-2 receptors in cancer patients.

  1994cited by this paper
• Detection of tumor necrosis factor soluble receptor p55 in blood samples from healthy and endotoxemic humans.

  1993cited by this paper
• Serum levels of tumor necrosis factor and soluble interleukin 2 receptor as markers of disease activity and prognosis in childhood leukemia and lymphoma.

  1993cited by this paper
• Tumor necrosis factor activities and cancer therapy--a perspective.

  1993cited by this paper
• Correlation between serum levels of soluble tumor necrosis factor receptor and disease activity in systemic lupus erythematosus.

  1993cited by this paper
• Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo.

  1992cited by this paper
• Elevated serum levels of soluble tumour necrosis factor receptors (sTNF‐R) in patients with HIV infection

  1992cited by this paper
• Induction of soluble tumour necrosis factor receptors during treatment with interleukin-2.

  1992cited by this paper
• High levels of circulating soluble receptors for tumor necrosis factor in hairy cell leukemia and type B chronic lymphocytic leukemia.

  1992cited by this paper
• Increased serum levels of soluble receptors for tumor necrosis factor in cancer patients.

  1991cited by this paper
• [TNF: antitumoral agent at the border lines of immunity and inflammation].

  1991cited by this paper
• A monoclonal antibody-based enzyme immunoassay for quantitation of human tumor necrosis factor binding protein I, a soluble fragment of the 60 kDa TNF receptor, in biological fluids.

  1991cited by this paper
• Purification and characterization of an inhibitor (soluble tumor necrosis factor receptor) for tumor necrosis factor and lymphotoxin obtained from the serum ultrafiltrates of human cancer patients.

  1990cited by this paper
• Molecular Cloning and Expression of Human and Rat Tumor Necrosis Factor Receptor Chain (p60) and Its Soluble Derivative, Tumor Necrosis Factor-Binding Protein

  1990cited by this paper
• Identification of two types of tumor necrosis factor receptors on human cell lines by monoclonal antibodies.

  1990cited by this paper
• Infusion of tumor necrosis factor (TNF) causes an increase in circulating TNF-binding protein in humans.

  1990cited by this paper
• Molecular cloning and expression of the human 55 kd tumor necrosis factor receptor.

  1990cited by this paper
• Molecular cloning and expression of a receptor for human tumor necrosis factor.

  1990cited by this paper
• Two tumor necrosis factor-binding proteins purified from human urine. Evidence for immunological cross-reactivity with cell surface tumor necrosis factor receptors.

  1990cited by this paper
• Purification and biologic characterization of a specific tumor necrosis factor alpha inhibitor.

  1989cited by this paper
• Continuous whole blood UltraPheresis procedure in patients with metastatic cancer.

  1989cited by this paper
• Isolation and characterization of a tumor necrosis factor binding protein from urine

  1989cited by this paper
• A tumor necrosis factor-binding protein purified to homogeneity from human urine protects cells from tumor necrosis factor toxicity.

  1989cited by this paper
• Two different cell types have different major receptors for human tumor necrosis factor (TNF alpha).

  1989cited by this paper
• Continuous whole blood UltraPheresis procedure in patients with metastatic cancer.

  1989cited by this paper
• A human inhibitor of tumor necrosis factor alpha

  1988cited by this paper
• The Development of New Immunotherapies for the Treatment of Cancer Using Interleukin‐2: A Review

  1988cited by this paper
• A tumor necrosis factor binding protein is present in human biological fluids

  1988cited by this paper
• Mechanism of rapid tumor lysis by human ADCC: mediation by monoclonal antibodies and fragmentation of target cell DNA.

  1985cited by this paper
• Recombinant murine GM‐CSF from E. coli has biological activity and is neutralized by a specific antiserum.

  1985cited by this paper
• Cytotoxic insult to tissue : effects on cell lineages

  1983cited by this paper
• An endotoxin-induced serum factor that causes necrosis of tumors.

  1975cited by this paper
• Role of the Thymus in the Recovery of Hemolytic Plaque Formation After X-Irradiation 1

  1971cited by this paper
• Role of the Thymus in Recovery of the Immune Mechanism in the Irradiated Adult Mouse

  1963cited by this paper
• The tumor-producing capacity of strain L mouse cells after 10 years in vitro.

  1956cited by this paper
• A semiautomatic needle for implanting tissues into experimental animals.

  1955cited by this paper

• Soluble B7 and TNF family in colorectal cancer: Serum level, prognostic and treatment value.

  2025cites this paper
• Duality of Interactions Between TGF-β and TNF-α During Tumor Formation

  2022cites this paper
• Recurrence of type 1 diabetes after beta-cell replacement

  2020cites this paper
• Mutations in the ND2 Subunit of Mitochondrial Complex I Are Sufficient to Confer Increased Tumorigenic and Metastatic Potential to Cancer Cells

  2019cites this paper
• Unleashing endogenous TNF-alpha as a cancer immunotherapeutic

  2018cites this paper
• The impact of herbal saponins on gut microflora in animal models

  2014cites this paper
• Interleukin-7 and Type 1 Diabetes

  2014cites this paper
• Concentration and Activity of the Soluble Form of the Interleukin-7 Receptor α in Type 1 Diabetes Identifies an Interplay Between Hyperglycemia and Immune Function

  2013cites this paper
• SERUM LEVELS OF TUMOR NECROSIS FACTOR (TNF-A) AND ITS SOLUBLE RECEPTORS STNF-R1 AND STNF-R2 IN CANCER PATIENTS

  2012cites this paper
• Evoked pain behavior and spinal glia activation is dependent on tumor necrosis factor receptor 1 and 2 in a mouse model of bone cancer pain.

  2010cites this paper
• Soluble IL-7Rα (sCD127) Inhibits IL-7 Activity and Is Increased in HIV Infection

  2010cites this paper
• Development of a Quantitative Bead Capture Assay for Soluble IL-7 Receptor Alpha in Human Plasma

  2009cites this paper
• Reduction of Plasma Levels of Soluble Tumor Necrosis Factor and Interleukin‐2 Receptors by Means of a Novel Immunoadsorption Column

  2008cites this paper
• Nociceptive characteristics of tumor necrosis factor-alpha in naive and tumor-bearing mice.

  2005cites this paper
• Tumor Necrosis Factor α Increases and α-Melanocyte-Stimulating Hormone Reduces Uveal Melanoma Invasion Through Fibronectin

  2003cites this paper
• Tumor necrosis factor alpha increases and alpha-melanocyte-stimulating hormone reduces uveal melanoma invasion through fibronectin.

  2003cites this paper
• Levels of the soluble, 55‐kilodalton isoform of tumor necrosis factor receptor in bone marrow are correlated with the clinical outcome of children with acute lymphoblastic leukemia in first recurrence

  2003cites this paper
• Tumor necrosis factor or tumor promoting factor?

  2002cites this paper
• Nitric Oxide Disrupts H2O2-dependent Activation of Nuclear Factor κB

  2001cites this paper
• Nitric oxide disrupts H2O2-dependent activation of nuclear factor kappa B. Role in sensitization of human tumor cells to tumor necrosis factor-alpha -induced cytotoxicity.

  2001cites this paper